Abstract
Increasing knowledge on cellular biology has permitted rapid changes in the treatment of metastatic melanoma. Until 2011, dacarbazine was the gold standard treatment at our disposal. In 2011 the treatment landscape changed dramatically with the approval by the FDA of ipilimumab and vemurafenib. These drugs use two new therapeutic approaches: immunomodulation and the targeting of mutated cellular pathways in tumor cells.
These two drugs, used as single agents have shown important increases in overall survival, unseen before in patients with advanced melanoma, but are limited by their toxicities and the appearance of acquired resistances.
In this article, we review new therapeutic options in pathway-targeted –with the arrival of MEK inhibitors - and immune based melanoma therapies –with the arrival of anti-PD1 and anti-PDL1- as well as new therapeutic strategies developed to overcome acquired resistance and diminish drug toxicities.
Keywords: anti-PD1, anti PDL1, BRAF inhibitors, combination therapies, dabrafenib, immune based therapies, ipilimumab, MEK inhibitors, melanoma, vemurafenib.
Anti-Cancer Agents in Medicinal Chemistry
Title:New Treatments for Cutaneous Metastatic Melanoma: MAPK Pathway-Targeted and Immune Based Therapies
Volume: 15 Issue: 4
Author(s): F. Ranchon, A. Boespflug, C. Rioufol, V. Schwiertz, L. Thomas and S. Dalle
Affiliation:
Keywords: anti-PD1, anti PDL1, BRAF inhibitors, combination therapies, dabrafenib, immune based therapies, ipilimumab, MEK inhibitors, melanoma, vemurafenib.
Abstract: Increasing knowledge on cellular biology has permitted rapid changes in the treatment of metastatic melanoma. Until 2011, dacarbazine was the gold standard treatment at our disposal. In 2011 the treatment landscape changed dramatically with the approval by the FDA of ipilimumab and vemurafenib. These drugs use two new therapeutic approaches: immunomodulation and the targeting of mutated cellular pathways in tumor cells.
These two drugs, used as single agents have shown important increases in overall survival, unseen before in patients with advanced melanoma, but are limited by their toxicities and the appearance of acquired resistances.
In this article, we review new therapeutic options in pathway-targeted –with the arrival of MEK inhibitors - and immune based melanoma therapies –with the arrival of anti-PD1 and anti-PDL1- as well as new therapeutic strategies developed to overcome acquired resistance and diminish drug toxicities.
Export Options
About this article
Cite this article as:
Ranchon F. , Boespflug A. , Rioufol C. , Schwiertz V. , Thomas L. and Dalle S. , New Treatments for Cutaneous Metastatic Melanoma: MAPK Pathway-Targeted and Immune Based Therapies, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (4) . https://dx.doi.org/10.2174/1871520615666150101125028
DOI https://dx.doi.org/10.2174/1871520615666150101125028 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes and aid in stabilizing chromosomal makeup. Resynthesis of telomeres supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no any telomerase activity in human somatic cells, but the stem cells and germ cells undergone telomerase ...read more
Role of natural compounds as anti anti-cancer agents
Cancer is considered the leading cause of worldwide mortality, accounting for nearly 10 million deaths in 2022. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy remains an important approach in treatment o f several types of cancers, even though ...read more
Signaling and enzymatic modulators in cancer treatment
Cancer accounts for nearly 10 million deaths in 2022 and is considered the leading cause of worldwide mortality. Cancer outcome can be improved through an appropriate screening and early detection and through an efficient clinical treatment. Chemotherapy, radiotherapy and surgery are the most important approach for the treatment of several ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Mechanisms of Thymoquinone as Anticancer Agent
Combinatorial Chemistry & High Throughput Screening Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
Current Pharmaceutical Design New Poly(3-hydroxybutyrate) Microparticles with Paclitaxel Sustained Release for Intraperitoneal Administration
Anti-Cancer Agents in Medicinal Chemistry A Neuroinformatics Study Describing Molecular Interaction of Cisplatin with Acetylcholinesterase: A Plausible Cause for Anticancer Drug Induced Neurotoxicity
CNS & Neurological Disorders - Drug Targets Drug-Mediated Targeted Disruption of Multiple Protein Activities Through Functional Inhibition of the Hsp90 Chaperone Complex
Current Medicinal Chemistry Nummular Eczema: An Updated Review
Recent Patents on Inflammation & Allergy Drug Discovery Novel Anticancer Strategy Aimed at Targeting Shelterin Complexes by the Induction of Structural Changes in Telomeric DNA: Hitting two Birds with one Stone
Current Cancer Drug Targets Focal Adhesion Kinase as a Cancer Therapy Target
Anti-Cancer Agents in Medicinal Chemistry Medical Evaluation of Human MicroRNAs Needs to Address Recent Sequences and GC Content
Current Regenerative Medicine (Discontinued) Interactome Analysis of the Differentially Expressed Proteins in Uterine Leiomyoma
Anti-Cancer Agents in Medicinal Chemistry Interplay of Breast Cancer Resistance Protein (BCRP) and Metabolizing Enzymes
Current Drug Metabolism Ursolic Acid Attenuates HMGB1-induced LOX-1 Expression in Vascular Endothelial Cells in vitro and Inhibits Atherogenesis in Hypercholesterolemic Mice in vivo
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Pharmacological Modulation of Nitric Oxide Release: New Pharmacological Perspectives, Potential Benefits and Risks
Current Medicinal Chemistry Comprehensive Analysis Reveals GPRIN1 is a Potential Biomarker for Non-sm all Cell Lung Cancer
Current Bioinformatics microRNAs as Anti-Cancer Therapy
Current Pharmaceutical Design Advances in Vaccine Adjuvants For Infectious Diseases
Current HIV Research Therapeutic Option of Plasmid-DNA Based Gene Transfer
Current Topics in Medicinal Chemistry The Relation Between the Chemical Structure of Flavonoids and Their Estrogen-Like Activities
Current Medicinal Chemistry Recombinant Human Serum Albumin Fusion Proteins and Novel Applications in Drug Delivery and Therapy
Current Pharmaceutical Design Natural Products Containing Olefinic Bond: Important Substrates for Semi-synthetic Modification Towards Value Addition
Current Organic Chemistry